Novartis Reports Long-term Survival Results From Metastatic Breast Cancer Combo Therapy

08:11 AM EST, 12/09/2025 (MT Newswires) -- Novartis (NOVN.SW) said Tuesday results from its phase 3 Monaleesa trials showed that its Kisqali inhibitor in combination with endocrine therapy led to the long-term progression-free survival of metastatic breast cancer patients. According to the three late-stage studies, one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer remained progression-free for at least four years following the combination therapy, with a median progression-free survival of 6.8 years. The Swiss drugmaker noted that Kisqali demonstrated "statistically significant" overall survival in all the trials and that the results were observed across all patients regardless of their menopausal status, as well as in participants with unfavorable prognostic factors.